Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Other Non-Current Liabilities (2020 - 2025)

Legend Biotech filings provide 6 years of Other Non-Current Liabilities readings, the most recent being $8.0 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 31.15% to $8.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.0 million, a 31.15% increase, with the full-year FY2025 number at $8.0 million, up 31.15% from a year prior.
  • Other Non-Current Liabilities hit $8.0 million in Q4 2025 for Legend Biotech, down from $8.1 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $8.1 million in Q3 2025 to a low of $554.0 in Q1 2021.
  • Median Other Non-Current Liabilities over the past 5 years was $224000.0 (2023), compared with a mean of $1.7 million.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 64159.93% in 2022 and later crashed 86.61% in 2024.
  • Legend Biotech's Other Non-Current Liabilities stood at $396000.0 in 2021, then tumbled by 41.16% to $233000.0 in 2022, then tumbled by 75.97% to $56000.0 in 2023, then surged by 10792.86% to $6.1 million in 2024, then skyrocketed by 31.15% to $8.0 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $8.0 million (Q4 2025), $8.1 million (Q3 2025), and $6.1 million (Q4 2024) per Business Quant data.